British Sovereign AI Fund eyes £500M bet on AI-driven drug discovery startup
The British Sovereign AI Fund is negotiating a £500 million investment in an AI-powered drug discovery startup, aiming to accelerate R&D and boost UK biotech.
Drug Discovery
Latest Drug Discovery coverage.
Anthropic's Claude designs 3.9 nM protein binder, validated by Carterra HT-SPR
Anthropic's Claude models autonomously designed protein binders, with Carterra's HT-SPR validating a 3.9 nM binder in weeks, not months.
Anthropic's AI models achieve 35.1% hit rate in protein binder campaign, outpacing field norm
Anthropic's AI models designed 354 binding proteins across 15 targets, with Mythos Preview hitting 35.1% in single-target mode, per the company's report.
ChronicleBio's $15M AI push analyzes 3,500 blood samples to tackle chronic diseases
ChronicleBio, co-founded by ex-OpenAI exec Fidji Simo, analyzes 3,500 blood samples with AI to cure chronic diseases, raises $15M.
Dimension closes $800M fund to fuel AI-biotech convergence
Dimension raises $800M to invest in AI-driven biotech startups, aiming to capitalize on the rapid ascent of AI in drug discovery.
Anthropic targets drug discovery with $2.7B clinical hurdle ahead
Anthropic enters pharmaceuticals to accelerate drug discovery, but experts highlight the $2.7B challenge of clinical trials.
Anthropic launches Claude Science to speed drug discovery, targets neglected diseases
Anthropic unveils Claude Science tool to accelerate drug research, focusing on overlooked diseases.